

Supporting Information

**Photoinduced CO-releasing molecule (photoCORM) as in situ CO
surrogate for palladium-catalysed aminocarbonylation**

Marcel Annereau,^a Michèle Salmain^a and Vincent Corcé ^{a*}

Table of content

I.	General information	2
II.	General procedures	2
	Synthesis of complex 1.....	2
	General procedure for the aminocarbonylation reaction	2
III.	Compound Characterization	3
IV.	NMR spectra	13
V.	References	42

I. General information

Unless otherwise noted, reactions were carried out under an argon atmosphere in oven-dried glassware. Reagents and chemicals were purchased from commercial sources and used as received. Infrared (IR) spectra were recorded on a Bruker Tensor 27 (equipped with ATR accessory, Pike) spectrophotometer. ^1H , ^{19}F , and ^{13}C NMR spectra were recorded at room temperature at 400 or 300, 377, and 100 or 75 MHz respectively, on a Bruker AVANCE 400 spectrometer or on a Bruker AVANCE 300 spectrometer. Chemical shifts (δ) are reported in ppm and coupling constants (J) are given in Hertz (Hz). Abbreviations used for peak multiplicity are: s (singlet); bs (broad singlet); d (doublet); t (triplet); q (quartet); quint (quintet); sept (septet); m (multiplet). Thin layer chromatography (TLC) was performed on Merck silica gel 60 F 254 and revealed with a UV lamp ($\lambda = 254$ nm) and KMnO_4 or vanillin staining. Flash Column Chromatography was conducted on silica Geduran® Si 60 Å (40 – 63 μm). High resolution mass spectrometry was performed a LTQ Orbitrap XL (Thermo Fisher Scientific) instrument equipped with an electrospray ion source in the positive mode. Reactions under argon were performed using standard Schlenk techniques. Brown glassware was employed for the formation of light-sensitive compounds. Manganese pentacarbonyl bromide ($[\text{Mn}(\text{CO})_5\text{Br}]$) was purchased from Strem chemicals. Sodium 8-hydroxyquinolate ligand was synthesized as described by Marshall.¹ Solvents were freshly distilled before use, according to standard procedures.

II. General procedures

Synthesis of complex 1.

This synthesis is a modification from our previous published protocol:²


In a 100 mL brown round bottom flask was added sodium 8-hydroxyquinolate (1 equiv., 5 mmol, 840 mg) and $\text{Mn}(\text{CO})_5\text{Br}$ (1 equiv., 5 mmol, 1.375 g). Tetrahydrofuran (50 mL) was added, followed by 1-methyl imidazole (1 equiv., 5 mmol, 400 μL). The reaction mixture was stirred for 12h at room temperature and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 98/2) to afford the complex **1** (1.7 g, 92%) as a yellow powder.

General procedure for the aminocarbonylation reaction

In a screw tube was successively added the aryl iodide **2** (1 equiv., 0.5 mmol), TEMPO (0.5 equiv., 0.25 mmol, 39 mg), complex **1** (0.5 equiv., 0.25 mmol, 91 mg), $\text{PdCl}_2(\text{PPh}_3)_2$ (5 mol %, 0.025 mmol, 17 mg), amine **3** (2 equiv., 1 mmol) and DBU (2 equiv., 1 mmol, 150 μL). Acetonitrile (2 mL) was added and the tube was screwed. The reaction mixture was irradiated with blue LEDs under stirring for 18h at room temperature. The reaction mixture was diluted with ethyl acetate (50 mL) and partitioned with a 1 M aqueous solution of hydrochloric acid (25 mL). The mixture was put under vigorous stirring until two clear phases were obtained. The organic layer was washed with 1 M HCl (25 mL), water (25 mL), brine

(25 mL) dried over MgSO_4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel to afford the expected amide **4**.


Set up for photo-reactions



A. Picture before irradiation. The distance between the tube and the LED source is 20 cm. **B.** Picture during irradiation.


Light source: Kessil Lamp. Wavelength: 450 nm. Power: 3 mW/cm² ($1.13 \cdot 10^{-8}$ einstein/s) at 20 cm distance between light source and reactor.

III. Compound Characterization



Following the general procedure with 4'-iodoacetophenone **2a** (0.5 mmol, 123 mg) and piperidine **3a** (1 mmol, 99 μL). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 20/80) to afford **4aa** as a white powder (100 mg, 86%). The spectroscopic data are in agreement with those reported in the literature.³


¹H NMR (400 MHz, CDCl_3) δ 7.95 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 3.68 (bs, 2H), 3.26 (bs, 2H), 2.58 (s, 3H), 1.73 – 1.41 (m, 6H). **¹³C NMR** (100 MHz, CDCl_3) δ 197.5, 169.1, 141.0, 137.6, 128.5, 127.0, 48.7, 43.1, 26.7, 26.5, 25.6, 24.5.



4ba

Following the general procedure with 4-fluoroiodobenzene **2b** (0.5 mmol, 58 μ L) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4ba** as a yellow oil (96 mg, 93%). The spectroscopic data are in agreement with those reported in the literature.⁴


¹H NMR (400 MHz, CDCl₃) δ 7.36 (dd, J = 8.5, 5.5 Hz, 2H), 7.04 (t, J = 8.7 Hz, 2H), 3.65 (s, 2H), 3.32 (s, 2H), 1.86 – 1.41 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 163.2 (d, J = 249.1 Hz), 132.5 (d, J = 3.4 Hz), 129.1 (d, J = 8.4 Hz), 115.5 (d, J = 21.7 Hz), 48.9, 43.3, 26.5, 25.7, 24.6. ¹⁹F NMR (376 MHz, CDCl₃) δ -110.97.



4ca

Following the general procedure with 1-chloro-4-iodobenzene **2c** (0.5 mmol, 120 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4ca** as a brown solid (90 mg, 80%). The spectroscopic data are in agreement with those reported in the literature.⁴


¹H NMR (400 MHz, CDCl₃) δ 7.47 – 7.29 (m, 4H), 3.67 (s, 2H), 3.31 (s, 2H), 1.81 – 1.41 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 135.4, 134.9, 128.7, 128.4, 48.9, 43.3, 26.6, 25.7, 24.6.



4da

Following the general procedure with 1-bromo-4-iodobenzene **2d** (0.5 mmol, 142 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4da** as a yellow powder (102 mg, 76%). The spectroscopic data are in agreement with those reported in the literature.⁵


¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 3.68 (bs, 2H), 3.32 (bs, 2H), 1.97 – 1.43 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 135.4, 131.8, 128.7, 123.7, 48.9, 43.4, 26.6, 25.7, 24.7.



Following the general procedure with 1,4-diiodobenzene **2e** (0.5 mmol, 165 mg) and piperidine **3a** (2 mmol, 200 μ L). The crude product was purified by flash column chromatography (cyclohexane/ ethyl acetate, 20/80) to afford **4ea** as a orange solid (80 mg, 53%). The spectroscopic data are in agreement with those reported in the literature.⁶


¹H NMR (400 MHz, CDCl₃) δ 7.40 (s, 4H), 3.70 (br, 4H), 3.31 (br, 4H), 1.67 (br, 8H), 1.49 (br, 4H).

¹³C NMR (100 MHz, CDCl₃) δ 169.7, 137.6, 132.0, 128.7, 128.6, 127.0, 48.8, 43.2, 26.6, 25.7, 24.6.




Following the general procedure with iodobenzene **2f** (0.5 mmol, 56 μ L) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4fa** as a colourless solid (77 mg, 81%). The spectroscopic data are in agreement with those reported in the literature.⁴

¹H NMR (300 MHz, CDCl₃) δ 7.38 (s, 5H), 3.70 (br, 2H), 3.34 (br, 2H), 1.80 – 1.60 (br, 4H), 1.52 (br, 2H). **¹³C NMR** (75 MHz, CDCl₃) δ 170.4, 136.7, 129.5, 128.5, 126.9, 48.9, 43.2, 26.7, 25.8, 24.7.



Following the general procedure with 4-iodobenzotrifluoride **2g** (0.5 mmol, 74 μ L mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4ga** as a pale yellow solid (98 mg, 76%). The spectroscopic data are in agreement with those reported in the literature.⁵


¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 3.72 (bs, 2H), 3.29 (bs, 2H), 1.60 (m, 6H). **¹³C NMR** (100 MHz, CDCl₃) δ 168.9, 140.2, 131.48 (q, J = 32.7 Hz), 127.3, 125.7 (q, J = 3.8 Hz), 123.9 (q, J = 272.3 Hz), 48.8, 43.3, 26.7, 25.7, 24.6. **¹⁹F NMR** (376 MHz, CDCl₃) δ -63.81.



4ha

Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 40/60) to afford **4ha** as a yellow powder (95 mg, 88%). The spectroscopic data are in agreement with those reported in the literature.⁵


¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 3.71 (bs, 2H), 3.27 (bs, 2H), 1.69 (bs, 4H), 1.51 (bs, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 168.3, 141.0, 132.5, 127.6, 118.3, 113.3, 48.8, 43.3, 26.6, 25.6, 24.5.



4ia

Following the general procedure with methyl 4-iodobenzoate **2i** (0.5 mmol, 131 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4ia** as a beige powder (85 mg, 68%). The spectroscopic data are in agreement with those reported in the literature.⁵


¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 3.92 (s, 3H), 3.71 (bs, 2H), 3.28 (bs, 2H), 1.68 (bs, 4H), 1.50 (bs, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 166.6, 141.0, 131.0, 129.9, 126.9, 52.4, 48.8, 43.2, 26.6, 25.7, 24.6.



4ja


Following the general procedure with 1-iodo-4-nitrobenzene **2j** (0.5 mmol, 124 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 30/70) to afford **4ja** as a yellow solid (89 mg, 76%). The spectroscopic data are in agreement with those reported in the literature.⁵

¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, J = 7.7 Hz, 2H), 7.55 (d, J = 7.6 Hz, 2H), 3.73 (s, 2H), 3.28 (s, 2H), 1.87 – 1.45 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 148.4, 142.9, 127.9, 124.0, 48.8, 43.3, 26.7, 25.6, 24.6.




Following the general procedure with 4-iodotoluene **2k** (0.5 mmol, 109 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4ka** as a reddish solid (60 mg, 60%). The spectroscopic data are in agreement with those reported in the literature.⁴

¹H NMR (300 MHz, CDCl₃) δ 7.28 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 7.9 Hz, 2H), 3.67 (br, 2H), 3.37 (br, 2H), 2.36 (s, 3H), 1.70 – 1.65 (br, 4H), 1.57 (br, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.6, 139.5, 133.7, 129.1, 127.0, 48.9, 43.3, 26.6, 25.8, 24.8, 21.5.




Following the general procedure with 2-iodotoluene **2l** (0.5 mmol, 64 μ L) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4la** as an orange powder (40 mg, 39%). The spectroscopic data are in agreement with those reported in the literature.⁵

¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.22 (m, 1H), 7.22 – 7.11 (m, 3H), 3.74 (m, 2H), 3.17 (m, 2H), 2.30 (s, 3H), 1.73 – 1.59 (m, 4H), 1.54 – 1.39 (m, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.0, 136.9, 134.1, 130.4, 128.7, 126.0, 125.7, 48.0, 42.5, 26.7, 25.9, 24.7, 19.1.



Following the general procedure with 3-iodotoluene **2m** (0.5 mmol, 64 μ L) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4ma** as an orange oil (64 mg, 60%). The spectroscopic data are in agreement with those reported in the literature.⁵


¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.21 (m, 1H), 7.20 – 7.11 (m, 3H), 3.68 (br, 2H), 3.32 (br, 2H), 2.35 (s, 3H), 1.65 (br, 4H), 1.49 (br, 2H). **¹³C NMR** (101 MHz, CDCl₃) δ 170.6, 138.3, 136.6, 130.1, 128.3, 127.5, 123.7, 48.8, 43.1, 26.6, 24.7, 21.5.



4na

Following the general procedure with 2-iodobenzonitrile **2n** (0.5 mmol, 114 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 40/60) to afford **4na** as a brown powder (60 mg, 56%). The spectroscopic data are in agreement with those reported in the literature.⁷


¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 7.8 Hz, 1H), 7.67 – 7.60 (m, 1H), 7.54 – 7.46 (m, 1H), 7.44 (d, J = 7.7 Hz, 1H), 3.77 (t, J = 5.0 Hz, 2H), 3.24 (t, J = 5.5 Hz, 2H), 1.93 – 1.49 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 166.4, 140.9, 133.2, 133.1, 129.4, 127.4, 117.0, 110.0, 48.5, 43.2, 26.5, 25.5, 24.5.



4oa

Following the general procedure with 4-iodoanisole **2o** (0.5 mmol, 117 mg) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 30/70) to afford **4oa** as a yellow oil (78 mg, 71%). The spectroscopic data are in agreement with those reported in the literature.⁵


¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 3.80 (s, 3H), 3.71 – 3.34 (m, 4H), 1.71 – 1.45 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 170.35, 160.55, 128.89, 128.65, 113.67, 55.37, 48.98, 43.46, 26.29, 24.70.



4pa


Following the general procedure with 1-iodonaphthalene **2p** (0.5 mmol, 73 μ L) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 50/50) to afford **4pa** as a brown powder (105 mg, 88%). The spectroscopic data are in agreement with those reported in the literature.⁸

¹H NMR (400 MHz, CDCl₃) δ 8.16 – 7.72 (m, 3H), 7.66 – 7.31 (m, 4H), 4.02 – 3.62 (m, 2H), 3.48 – 3.01 (m, 2H), 2.02 – 1.54 (m, 4H), 1.46 – 1.32 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 135.0, 133.6, 129.7, 128.9, 128.4, 126.9, 126.5, 125.3, 125.0, 123.5, 48.4, 42.8, 26.8, 26.0, 24.7.




Following the general procedure with 4-*tert*-butyliodobenzene **2q** (0.5 mmol, 89 μ L) and piperidine **3a** (1 mmol, 99 μ L). The crude product was purified by flash column chromatography (cyclohexane/ diethyl ether, 60/40) to afford **4qa** as a yellow solid (86 mg, 70%). The spectroscopic data are in agreement with those reported in the literature.⁵

¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H), 3.70 (bs, 2H), 3.38 (bs, 2H), 1.80 – 1.48 (m, 6H), 1.32 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.6, 152.6, 133.7, 126.8, 125.4, 48.9, 43.2, 34.9, 31.3, 26.7, 25.8, 24.8.




Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and pyrrolidine **3b** (1 mmol, 84 μ L). The crude product was purified by flash column chromatography (cyclohexane/ ethyl acetate, 34/66) to afford **4hb** as a brownish solid (70 mg, 70%). The spectroscopic data are in agreement with those reported in the literature.⁹

¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 8.3 Hz, 2H), 7.60 – 7.54 (d, J = 8.3 Hz, 2H), 3.60 (t, J = 6.9 Hz, 2H), 3.33 (t, J = 6.5 Hz, 2H), 2.01 – 1.75 (m, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 167.5, 141.3, 132.2, 127.7, 118.1, 113.4, 49.3, 46.3, 26.3, 24.3.




Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and morpholine **3c** (1 mmol, 87 μ L). The crude product was purified by flash column chromatography (cyclohexane/ ethyl acetate, 50/50) to afford **4hc** as a brown powder (54 mg, 50%). The spectroscopic data are in agreement with those reported in the literature.¹⁰

¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 3.77 (s, 4H), 3.68 – 3.52 (m, 2H), 3.37 (s, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 168.3, 139.7, 132.5, 127.8, 118.0, 113.7, 66.7.




Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and *N,N*-diethylamine **3d** (1 mmol, 103 μ L). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 50/50) to afford **4hd** as a brown powder (70 mg, 69%). The spectroscopic data are in agreement with those reported in the literature.¹¹

¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 3.55 (bs, 2H), 3.20 (bs, 2H), 1.36 – 1.03 (m, 6H). **¹³C NMR** (75 MHz, CDCl₃) δ 169.3, 141.7, 132.5, 127.2, 118.3, 113.2, 43.4, 39.6, 14.3, 13.0.




Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and phenethylamine **3f** (1 mmol, 126 μ L). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 34/66) to afford **4hf** as a yellow powder (80 mg, 64%). The spectroscopic data are in agreement with those reported in the literature.¹²

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.39 – 7.20 (m, 5H), 6.27 (s, 1H), 3.75 (q, J = 6.9 Hz, 2H), 2.97 (t, J = 6.9 Hz, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.8, 138.7, 138.6, 132.6, 128.9, 128.9, 127.7, 126.9, 118.1, 115.1, 41.4, 35.6.



Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and benzylamine **3g** (1 mmol, 109 μ L). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 50/50) to afford **4hg** as a yellow powder (75 mg, 63%). The spectroscopic data are in agreement with those reported in the literature.¹²


¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.39 – 7.28 (m, 5H), 6.64 (s, 1H), 4.63 (d, J = 5.5 Hz, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.7, 138.4, 137.7, 132.6, 129.0, 128.1, 128.0, 127.8, 118.1, 115.2, 44.5.



4hh

Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and isopentylamine **3h** (1 mmol, 116 μ L). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 50/50) to afford **4hh** as a yellow solid (50 mg, 46%).


¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H), 6.39 (s, 1H), 3.52 – 3.36 (m, 2H), 1.73 – 1.57 (m, 1H), 1.54 – 1.43 (m, 2H), 0.94 (s, 3H), 0.92 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.8, 138.9, 132.5, 127.7, 118.1, 114.9, 38.8, 38.5, 26.0, 22.5. **IR**: ν (CN) 2230, ν (CO) 1636 cm⁻¹. **HRMS** (ESI) m/z : [M+H]⁺ Calcd for C₁₃H₁₆N₂OH 217.1335. Found 217.1335.



4hi

Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and 4-(2-aminoethyl)morpholine **3i** (1 mmol, 131 μ L) but the work-up was performed with a 1M solution of KOH instead of 1M HCl. The crude product was purified by flash column chromatography (CH₂Cl₂/MeOH, 98/2) to afford **4hi** as a yellow solid (80 mg, 62%).


¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 8.5 Hz, 2H), 6.86 (s, 1H), 3.85 – 3.63 (m, 4H), 3.66 – 3.45 (m, 2H), 2.61 (t, J = 6.0 Hz, 2H), 2.56 – 2.51 (m, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.7, 138.6, 132.6, 127.8, 118.2, 115.2, 67.1, 56.8, 53.4, 36.3. **IR**: ν (CN) 2235; ν (CO) 1639 cm⁻¹. **HRMS** (ESI) m/z : [M+H]⁺ Calcd for C₁₄H₁₇N₃O₂H 260.1394. Found 260.1394.



4hj


Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and *sec*-butylamine **3j** (1 mmol, 101 μ L). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 50/50) to afford **4hj** as a beige powder (86 mg, 85%). The spectroscopic data are in agreement with those reported in the literature.

¹H NMR (300 MHz, CDCl₃) δ 7.85 (d, J = 8.5 Hz, 2H), 7.72 (d, J = 8.4 Hz, 2H), 5.98 (s, 1H), 4.12 (dq, J = 8.4, 6.6 Hz, 1H), 1.59 (p, J = 7.3 Hz, 2H), 1.24 (d, J = 6.6 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 165.3, 139.1, 132.5, 127.7, 118.2, 115.0, 47.7, 29.8, 20.5, 10.5. **IR**: ν (CN) 2235; ν (CO) 1634 cm⁻¹. **HRMS** (ESI) m/z : [M+H]⁺ Calcd for C₁₂H₁₄N₂OH 203.1179. Found 203.1179.




Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and adamantylamine **3k** (1 mmol, 151 mg). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 50/50) to afford **4hk** as a white powder (61 mg, 44%). The spectroscopic data are in agreement with those reported in the literature. 2229, 1640.

¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 8.4 Hz, 2H), 7.70 (d, *J* = 8.3 Hz, 2H), 5.82 (s, 1H), 2.19 – 2.06 (m, 9H), 1.77 – 1.66 (m, 6H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.9, 140.1, 132.5, 127.6, 118.2, 114.7, 53.0, 41.7, 36.4, 29.6. **IR**: ν(CN) 2229; ν(CO) 1640 cm⁻¹. **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₈H₂₀N₂OH 281.1648. Found 281.1648.



Following the general procedure with 4-iodobenzonitrile **2h** (0.5 mmol, 114 mg) and *tert*-butylamine **3l** (1 mmol, 105 μL). The crude product was purified by flash column chromatography (cyclohexane/diethyl ether, 60/40) to afford **4hl** as a yellow solid (30 mg, 30%). The spectroscopic data are in agreement with those reported in the literature.¹³


¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 7.8 Hz, 2H), 7.70 (d, *J* = 7.7 Hz, 2H), 5.97 (s, 1H), 1.47 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.2, 140.0, 132.5, 127.6, 118.2, 114.8, 52.3, 28.9.




Following the general procedure with 4-chlorobenzene **2c** (0.5 mmol, 120 mg) and 4-(2-aminoethyl)morpholine **3i** (1 mmol, 131 μL) but the work-up was performed with a 1M solution of KOH instead of 1M HCl. The crude product was purified by flash column chromatography (CH₂Cl₂/MeOH, 97/3) to afford **Moclobemide** as a yellow solid (107 mg, 79%). The spectroscopic data are in agreement with those reported in the literature.¹⁴

¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.6 Hz, 2H), 7.44 (d, *J* = 8.5 Hz, 2H), 6.78 (s, 1H), 3.92 – 3.73 (m, 4H), 3.61 – 3.46 (m, 2H), 2.62 (t, *J* = 6.0 Hz, 2H), 2.56 – 2.42 (m, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 166.3, 137.6, 133.0, 128.8, 128.4, 67.0, 56.8, 53.3, 36.1.


IV. NMR spectra ¹H NMR spectrum of 4aa




¹³C NMR spectrum of 4aa




¹H NMR spectrum of 4ba




¹³C NMR spectrum of 4ba




^{19}F NMR spectrum of **4ba**




^1H NMR spectrum of **4ca**




¹³C NMR spectrum of **4ca**



¹H NMR spectrum of **4da**




¹³C NMR spectrum of 4da




¹H NMR spectrum of 4ea

MAN-2-104.30.fid — 1,4-diodobenzene purif 2




¹³C NMR spectrum of 4ea

MAN-2-104.70.fid —




¹H NMR spectrum of 4fa

MAN-2-82.20.fid —




¹³C NMR spectrum of 4fa


MAN-2-82.21.fid —




¹H NMR spectrum of 4ga




^{13}C NMR spectrum of 4ga




^{19}F NMR spectrum of 4ga




¹H NMR spectrum of 4ha




¹³C NMR spectrum of 4ha




¹H spectrum for 4ia




¹³C spectrum for 4ia



¹H NMR spectrum of 4ja




¹³C NMR spectrum of 4ja




¹H NMR spectrum of 4ka

MAN-2-83.10.fid — 4 iodotoluene




¹³C NMR spectrum of 4ka

MAN-2-3.11.fid —




¹H NMR spectrum of 4Ia

MAN-2-103.52.fid —




¹³C NMR spectrum of 4Ia

MAN-2-103.53.fid —




¹H NMR spectrum of 4ma

MAN-2-84.50.fid —




¹³C NMR spectrum of 4ma


MAN-2-84.51.fid —




¹H NMR spectrum of 4na




¹³C NMR spectrum of 4na




¹H NMR spectrum of 4oa




¹³C NMR spectrum of 4oa




¹H NMR spectrum of **4pa**




¹³C NMR spectrum of **4pa**



¹H NMR spectrum of **4qa**




¹³C NMR spectrum of **4qa**




¹H NMR spectrum of 4hb

MAN-2-129purif1.10.fid — pyrrolidin pur




¹³C NMR spectrum of 4hb

MAN-2-129purif1.11.fid — pyrrolidin pur




¹H NMR spectrum of 4hc

morpholine purif




¹³C NMR spectrum of 4hc


morpholine purif



¹H NMR spectrum of 4hd




¹³C NMR spectrum of 4hd




¹H NMR spectrum of 4hf

MAN-2-130purif1.10.fid — phenylethylamine pur




¹³C NMR spectrum of 4hf

MAN-2-130purif1.11.fid — phenylethylamine pur




¹H NMR spectrum of 4hg

MAN-2-134total.10.fid — benzylamine purif




¹³C NMR spectrum of 4hg

MAN-2-134total.11.fid — benzylamine purif




¹H NMR spectrum of 4hh

MAN-2-138total.22.fid — isopentylamine




¹³C NMR spectrum of 4hh


MAN-2-138total.23.fid — isopentylamine purif




¹H NMR spectrum of 4hi




¹³C NMR spectrum of 4hi



¹H NMR spectrum of 4hj




¹³C NMR spectrum of 4hj




¹H NMR spectrum of 4hk

MAN-2-136total.10.fid — adamantylamine purif




¹³C NMR spectrum of 4hk


MAN-2-136total.11.fid — adamantylamine purif




¹H NMR spectrum of 4hl




¹³C NMR spectrum of 4hl



¹H NMR spectrum of Moclobemide



¹³C NMR spectrum of Moclobemide



V. References

- 1 W. O. Foye and J. R. Marshall, *J. Pharm. Sci.*, 1964, **53**, 1338–1341.
- 2 M. Annereau, F. Martial, J. Forté, G. Gontard, S. Blanchard, H. Dossmann, M. Salmain and V. Corcé, *Appl. Organomet. Chem.*, 2023, **37**, e7171.
- 3 H. L. Holland, T. A. Morris, P. J. Nava and M. Zabic, *Tetrahedron*, 1999, **55**, 7441–7460.
- 4 J. Li, F. Xu, Y. Zhang and Q. Shen, *J. Org. Chem.*, 2009, **74**, 2575–2577.
- 5 M. Zhu, K. Fujita and R. Yamaguchi, *J. Org. Chem.*, 2012, **77**, 9102–9109.
- 6 J. A. Moore and S. Kaur, *Macromolecules*, 1997, **30**, 7086–7090.
- 7 W. Liu and L. Ackermann, *Chem. Commun.*, 2014, **50**, 1878–1881.
- 8 F. Messa, A. N. Paparella, D. Veselý, J. Krajčovič, P. Papadia, S. Perrone and A. Salomone, *Eur. J. Org. Chem.*, 2023, **26**, e202300309.
- 9 K. Ekoue-Kovi and C. Wolf, *Org. Lett.*, 2007, **9**, 3429–3432.
- 10 D. Dvorak, *Organometallics*, 1995, **14**, 570–573.
- 11 R. S. Mane and B. M. Bhanage, *J. Org. Chem.*, 2016, **81**, 1223–1228.
- 12 T. Kumar Achar and P. Mal, *Adv. Synth. Catal.*, 2015, **357**, 3977–3985.
- 13 H. Jiang, B. Liu, Y. Li, A. Wang and H. Huang, *Org. Lett.*, 2011, **13**, 1028–1031.
- 14 A. Ghanbarpour, F. Hadizadeh, F. Piri and P. Rashidi-Ranjbar, *Pharm. Acta Helv.*, 1997, **72**, 119–122.